Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe
Access to CAR T-cell therapies varied widely across European countries. Faster access to these therapies can result in significant health gains. Ensuring prompt and equitable access to innovative therapies requires proactive alignments between manufacturers and HTA bodies, possibly through mechanisms such alternative pricing models and risk-sharing agreements.
Authors
- Matthew Madin-Warburton
- Emily Breislin
- Daniel Gladwell (ORCID: https://orcid.org/0000-0002-1642-2924)
- A Zang
- Sachin Vadgama (ORCID: https://orcid.org/0000-0002-9138-8471)
- Adriana Wiesinger
- Yan Zhi Tan
- Brett Doble
- Oriol Sola-Morales
- Matthew Woods
Institutions
- Universitat Internacional de Catalunya (ES)
- Gilead Sciences (United Kingdom) (GB)
- National Health Insurance Fund (RS)
- Gilead Sciences (Australia) (AU)
- Gilead Sciences (France) (FR)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1080/13696998.2026.2626239
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00